About the R&D of Kelun

The R&D of Kelun



Innovation is the spirit of enterprise competition. Kelun made the most of medical talents and other competitive resources at home and abroad. The company established an R&D system with multiple technical categories and a fully functional platform, which includes the Chengdu and Suzhou Research Institutes as the main body committing to high-end generics, Kelun-Biotech and KLUS (the U.S. branch) as the main body focusing on innovation research. This is a new kind of R&D mode fully in line with international standards, under which research is mainly led by domestic institutes with the help of foreign technology.  Kelun also has an R&D team with more than 2000 researchers and has introduced more than 200 leading scientists with rich R&D experience from well-known enterprises at home and abroad. Now, the company has basically built an advanced technology platform and a high-efficiency international standard R&D team led by excellent talents for many key technical fields such as pharmaceutical preparations, infusions, NDDS (Novel Drug Delivery System) drugs, branded generics, innovative small molecule drugs, biotechnology drugs, pharmaceutical evaluation and clinical research.
Kelun sticks to investing more than 10% of sales revenue in R&D every year, mainly focusing on the development of drugs urgently needed in clinical practice, such as branded generics, high-end infusions, NDDS, innovative small molecules, and biotechnology drugs. The company has rapidly completed the construction of major technology platforms and the layout of drugs for the treatment of major diseases, covering different drug categories for present and future, domestic and foreign, generics and innovation, macromolecules and small molecules, drug release systems. Kelun has initiated the development of more than 300 critical drugs in multiple fields, such as tumors, infection, diabetes, etc. The company has successfully out-licensed several innovative patents to world-famous pharmaceutical companies. According to the report from Nature, Kelun`s total deal value ranked first amount the Top 10 biopharma partnerships worldwide in 2022, which represents that Kelun's drug research and development has successfully entered the virtuous circle of "generics-driven innovation and innovation-driven future" in the global market and has stepped into the front rank of innovation capability of Chinese pharmaceutical companies.